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Background: This study is to evaluate the toxicity and outcomes of helical tomotherapy (HT) in patients treated for
unresectable hepatocellular carcinoma (HCC).
Methods: From March 2008 to September 2010, 38 patients with unresectable HCC were treated with HT. The median
patient age was 67 years (range, 45–85). The median follow-up period was 17.2 months (range, 7–46). All patients had
liver cirrhosis. Median radiation dose was 54 Gy (range, 46–71.8) delivered in 1.8 to 2.4-Gy fractions. The planning target
volumes were 241.2 ± 153.1 cm3 (range, 45.8–722.4). Treatment responses were assessed in 3–6 months after HT.
Results: There was a complete response in 2 patients (5.2 %), partial response in 18 patients (47.4 %), stable disease in
13 patients (34.2 %), and progressive disease in 5 patients (13.2 %). The median overall survival was 12.6 months,
and 1- and 2-year overall survival rates were 56.2 and 31.7 %, respectively. Eastern Cooperative Oncology Group
(ECOG score, p = 0.008), Child-Pugh classification (p = 0.012), albumin (p = 0.046), and hemoglobin (p = 0.028) were
significant parameters that predicted primary tumor response to radiotherapy in multivariate analysis. ECOG score
(p = 0.012), Child-Pugh class (p = 0.026), and response to radiotherapy (p = 0.016) were independent prognostic
factors for overall survival in multivariate analysis. Responders had better overall survival than non-responders
(23.6 vs. 5.8 months, p < 0.001). The 1- and 2-year overall survival rates for responders were 68.3 and 57 %, respectively,
while for non-responders, they were 0 %. The 1- and 2-year local control rates were 88.2 and 82.3 %, respectively.
Five patients (13.2 %) had grade 3 or greater liver toxicity, and one patient (2.6 %) had a grade 3 gastric ulcer. No
treatment-related liver failure or death was documented in this study.
Conclusions: Radiotherapy using HT seems to be a safe and effective treatment option for unresectable HCC patients.
This study indicates that HT is a feasible treatment even in patients without good performance status and hepatic
function reservation.
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Hepatocellular carcinoma (HCC) is the fifth most fre-
quently diagnosed cancer in men and the second reason of
cancer-related mortality in the world [1]. In women, it is
the seventh most common cancer and sixth leading cause
of cancer death. Because of the prevalence of hepatitis B* Correspondence: ccjjhh@kmu.edu.tw
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creativecommons.org/publicdomain/zero/1.0/and C, the incidence of HCC is particularly high in East
Asia and Africa [2]. Complete surgical resection and hep-
atic transplantation is considered a curative therapy for
HCC, but only less than 15 % of patients with HCC are
indicated for curative surgery because of tumor extent or
compromised hepatic function [3, 4]. It remains challen-
ging to treat patients with unresectable HCC, and most of
them have dismal prognosis. Several other treatment mo-
dalities for patients with unresectable HCC, including
percutaneous ethanol injection (PEI), radiofrequency abla-
tion (RFA), and transcatheter arterial chemoembolizationrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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are contraindicated in patients with portal vein tumor
thrombosis (PVTT), ascites, or biliary obstruction.
Given the risks of radiation-induced liver disease (RILD)
and even liver failure and low tolerance of whole liver ir-
radiation, radiotherapy (RT) has played a limited role in
managing advanced HCC with conventional RT tech-
niques [5]. The limitation is more prominent in HCC
patients with underlying liver cirrhosis, which is prone to
decompensated liver disease. With the advent of intensity-
modulated radiotherapy (IMRT) and image-guided radio-
therapy (IGRT), higher tumoricidal dosage could be more
safely and precisely delivered to liver tumor and might
theoretically increase local tumor control [6, 7]. Emerging
evidence has shown that partial liver irradiation with
three-dimensional conformal radiation therapy (3D-CRT)
resulted in low toxicity and long-term tumor control in
patients with unresectable HCC [8, 9]. However, the treat-
ment techniques, fractionation, and total doses of RT for
patients with HCC have varied greatly within different
studies.
Helical tomotherapy (HT) uses modulated treatment
apertures (defined by dynamic multi-leaf collimator) and
dose rate to improve target conformality, dose homogen-
eity, and normal tissue sparing compared to 3D-CRT
and/or IMRT. The on-board megavoltage computed
tomography (CT) detection allows for daily setup verifi-
cation, which can minimize planning target margins and
irradiated normal tissues. With integrating IGRT with
IMRT, HT could deliver higher dose to the relatively
large tumor without increasing the normal tissue dam-
age. However, there have been a few clinical reports
regarding oncologic outcomes and tolerance of HCC pa-
tients receiving HT. This retrospective study aimed at
evaluating the efficacy and toxicity of HT for cirrhotic
patients with unresectable HCC.
Methods
Patient selection
The diagnosis of HCC was made according to histopath-
ology (n = 13) or the typical radiologic features in a
cirrhotic liver with or without an elevated serum alpha-
fetoprotein (AFP) level (n = 25). Typical images to diag-
nose the presence of HCC in a mass lesion greater than
2 cm in greatest dimension with hypervascularity were
taken. Unresectable tumor was defined by extensive
tumor, major vascular invasion, or a poor medical con-
dition that disallows surgical resection. The inclusion
criteria in this study were primary HCC confirmed by
biopsy or imaging, patients considered unresectable,
and age >18 years. Patients who had extrahepatic me-
tastases, Eastern Cooperative Oncology Group (ECOG)
score ≧3, Child-Pugh class C disease or double cancer
were excluded. Sixty-four HCC patients treated withHT were enrolled in our hospital between March 2008
and February 2011. Among them, 26 patients were ex-
cluded; 17 patients had evidence of distant metastases,
5 did not complete the planned RT, 2 had prior abdominal
irradiation, and 2 had other malignancies. Finally, 38 pa-
tients were evaluated in the current study. Written in-
formed consent was obtained from all the patients, and
this retrospective study was approved by the Institutional
Review Board of Kaohsiung Medical University Chung-Ho
Memorial Hospital (KMUH-IRB-20120155).
Treatment
CT simulation was performed for each patient with 5-mm
slice thickness without contrast medium. All patients were
immobilized with a posterior vacuum-lock body fixation
device and an anterior vacuum-sealed cover sheet to re-
duce respiration movement. To further diminish liver mo-
tion by breathing, all patients were educated to breathe
shallowly and not to fight with the compression of anter-
ior cover sheet. The gross tumor volume (GTV), including
PVTT, was delineated according to contrast-enhancing
tumor exhibiting on diagnostic CT or magnetic resonance
imaging (MRI) images. The whole intrahepatic tumor was
included in the GTV with physician’s concern about
tumor size, preserved liver function, and the irradiated
volume of the liver. A margin of 1 to 1.5 cm was added to
the GTV to cover microscopic tumor extension. Another
0.5 to 1 cm radical margin and 1 to 1.5 cm craniocaudal
margin were added to count for organ motion and setup
errors (planning target volume (PTV)). The entire liver
was contoured, and the normal liver volume was defined
as the whole liver volume minus the GTV. Treatment plan-
ning was generated using Tomotherapy planning software,
version 4.0 (Tomotherapy, Madison, WI). Total prescribed
dose depended on the individual physician’s decision [10].
HT was delivered once per day, five times a week. Before
each treatment, a megavoltage CT scan was performed to
correct the displacement of tumors and internal organs
automatically or manually.
Prescribing tumor dose to the 95 % isodose line to en-
compass the PTV was required. The organs at risk used in
current study were (1) spinal cord: maximum dose ≤45 Gy;
(2) kidneys: mean dose to bilateral kidneys must be <15
Gy, and no more than 30 % of the volume of kidney
can receive ≥20 Gy; (3) liver: mean normal liver dose
must be ≤28 Gy, and no more than 30 % of normal liver
can receive ≥30 Gy (V30 < 30 %); and (4) stomach and
small bowels: maximum dose ≤45 Gy.
Follow-up and response evaluation
The tumor response was evaluated by contrast-enhanced
CT scans or MRIs at 3 to 6 months after the completion
of RT. The response evaluation to criteria in solid tumors
(RECIST) was used to determine the tumor response after
Table 1 Baseline characteristics of patients
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complete disappearance of the irradiated tumor. Partial re-
sponse (PR) represented at least a 30 % reduction of
tumor in the greatest dimension. Progressive disease (PD)
was defined as at least a 20 % increase of tumor in the
greatest dimension, and stable disease (SD) was defined as
any tumor volume change other than PR or PD. Patients
with CR or PR after RT were defined as responders, and
non-responders represented patients with SD or PD. Local
control was defined as image-based absence of disease
progression. Patients with CR, PR, or SD were categorized
as a condition of local control of disease.
Treatment associated side effects were evaluated weekly
during RT and at each follow-up visit after treatment. Late
toxicity was determined when toxicity occurred 3 months
after the completion of treatment. The toxicity was assessed
according to Radiation Therapy Oncology Group toxicity
criteria [12]. Radiation-induced liver disease was defined as
the development of nonmalignant ascites without disease
progression and an anicteric increase in the alkaline-
phosphatase level at least twofold or in the transaminase
level at least fivefold after RT [13].
Statistical analysis
Chi-square test, Fisher’s exact test, or t test was used to
determine the association between tumor response and
various parameters. Parameters with a p value less than
0.05 in univariate analysis were further evaluated in
multivariate analysis, using logistic regression model.
The overall survival (OS) was calculated from the start
of RT to the date of death or last follow-up visit. Time
to local failure was defined from the beginning of the
treatment until progression. Rates were estimated using
the Kaplan-Meier method and compared the effect of
each variable on the survival using the log-rank test.
Parameters with a p value less than 0.05 in univariate
analysis were further evaluated in multivariate analysis,
using Cox regression hazard model. Data analyses were
conducted with the JMP software (version 9.0, SAS Insti-
tute Inc., Cary, NC). Results were considered significant
at p values < 0.05.
Results
Patient characteristics
Thirty-one men and 7 women were enrolled. The me-
dian patient age was 67 years (range, 45–85). All pa-
tients had liver cirrhosis. 27 patients (71.1 %) were
Child-Pugh class A, and 11 patients (28.9 %) were class
B. There were 24 patients (63.2 %) with portal vein
tumor thrombosis. Twenty-nine patients underwent
median 3 cycles (range, 1–9) of TACE (range, 1–9), and
18 patients received PEI or RFA, but all of them experi-
enced poor treatment response or disease progression.
HT was delivered as the first treatment for 3 patientsbecause of contraindications for other treatment mo-
dalities. The characteristics of the 38 patients are
shown in Table 1.
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The median RT dose was 54 Gy (range, 46–71.8 Gy).
Because of different doses per fraction used in the study,
the biologically effective doses (BED) were also assessed
and are summarized in Table 2. The mean volume of
PTV was 241.2 cm3 (range, 44.8–722.4), and the mean
normal liver volume was 987.7 cm3 (range, 391.5–1515.4).
The mean normal liver V30 was 12.8 % (range, 3–27 %).
The mean dose to normal liver was 17.6 Gy (range, 6–28),
and the average V10, V18, and V40 of normal liver were
64.6, 32.7, and 6.4 %, respectively. The mean doses to the
right kidney, left kidney, small bowel, and stomach were
8.6, 3.2, 4.6, and 6.7 Gy, respectively.Tumor response rates
Median follow-up time was 17.2 months (range, 7–46).
All patients were evaluable for the tumor response.
There was CR in 2 patients (5.2 %), PR in 18 patients
(47.4 %), SD in 13 patients (34.2 %), and PD in 5 patientsTable 3 Predictive factors for local control
Univariate analysis
Parameters Hazard ratio (95 % CI)
Age (≤67/>67) years 1.13 (0.49–2.78)
Gender (male/female) 0.75 (0.31–1.76)
ECOG score (0–1/2) 1.13 (0.48–2.84)
Etiology (viral/non-viral) 1.01 (0.79–1.27)
Child-Pugh class (A/B) 0.87 (0.74–0.96)
AFP (≤400/>400) ng/ml 0.83 (0.76–0.93)
Albumin (>3.6/≤3.6) g/dL 0.88 (0.71–0.91)
Hemoglobin (>11/≤11) g/dL 0.72 (0.64–0.88)
PVTT (no/yes) 2.36 (0.87–6.39)
BED (>65.5/≤65.5) Gy10 0.78 (0.69–0.92)
RT duration (≤37/>37) days 1.07 (0.92–6.34)
PVTT portal vein tumor thrombus, HCC hepatocellular carcinoma, ECOG Eastern Coo
AFP Alpha-fetoprotein(13.2 %). The objective tumor response rate was 52.6 %.
Univariate analysis showed that ECOG score, Child-Pugh
classification, albumin, hemoglobin, mean BED, and mean
RT duration were statistically significant predictors of
tumor response. ECOG score (p = 0.008), Child-Pugh clas-
sification (p = 0.012), albumin (p = 0.046), and hemoglobin
(p = 0.028) remained significant in multivariate analysis.
The 1- and 2-year local control rates were 88.2 and
82.3 %, respectively. Patients with Child-Pugh B, AFP >
400 ng/ml, albumin ≤ 3.6 g/dL, hemoglobin ≤ 11 g/dL, or
BED ≤ 65.5 Gy10 were more likely to relapse. In multivari-
ate analysis, a higher BED remained significantly associ-
ated with a lower risk of relapse (hazard ratio (HR) = 0.78;
95 % confidence interval (CI), 0.69–0.92; p = 0.023). AFP
(HR = 0.81; 95 % CI, 0.74–0.93; p = 0.011) and Child-Pugh
classification (HR = 0.85; 95 % CI, 0.69–0.98; p = 0.022)
were also associated with higher risk of local failure.
Results are presented in Table 3.
Survival analysis and predictors of survival
At the time of analysis, 31 patients had died and 7 pa-
tients remained alive. The median survival time was 12.6
months (range, 3.6–40.9), with 1- and 2-year survival
rates of 56.2 and 31.7 %, respectively.
On the log-rank test, poor ECOG score, Child-Pugh
class B, albumin ≤ 3.6 g/dL, and response to RT were sig-
nificant unfavorable prognostic factors for overall survival.
In Cox regression analysis, ECOG score (p = 0.012), Child-
Pugh class (p = 0.026), local tumor control (p = 0.011), and
response to radiotherapy (p = 0.016) were independent
prognostic factors for overall survival (Table 4). For patients
achieving tumor response (CR + PR), the median survival
time was 27.8 ± 8.5 months, which was much higher than
6.2 ± 2.8 months of non-responders. The 1- and 2-year
overall survival rates for responders were 68.3 and 57 %,Multivariate analysis
P value Hazard ratio (95 % CI) P value
0.772 1.01 (0.97–1.07) 0.762
0.519 1.33 (0.46–3.95) 0.585
0.778 1.73 (0.66–4.94) 0.264
0.959 2.17 (0.61–8.28) 0.227
0.003 0.85 (0.69–0.98) 0.022
<0.001 0.81 (0.74–0.93) 0.011
0.049 1.26 (0.52–6.41) 0.231
0.044 1.41 (0.59–6.86) 0.213
0.091 1.66 (0.68–5.12) 0.121
0.023 0.81 (0.71–0.93) 0.032
0.029 1.52 (0.41–5.24) 0.512
perative Oncology Group, BED biologically effective dose, RT radiation therapy,









≤ 67 8.5 ± 5.5
> 67 7.2 ± 4.7
Gender 0.225
Male 8.5 ± 6.2
Female 6.3 ± 2.8
ECOG score <0.001 0.012
0–1 9.5 ± 7.2
2 3.8 ± 1.6
Etiology 0.153
Viral 8.5 ± 5.5
Non-viral 6.6 ± 5.5
Child-Pugh class <0.001 0.026
A 8.5 ± 7.2
B 5.2 ± 1.6
AFP (ng/ml) 0.890
≤ 400 8.5 ± 6.2
> 400 7.2 ± 2.8
Albumin (g/dL) 0.003 0.076
≤ 3.6 6.6 ± 2.8
> 3.6 15.2 ± 6.2
Hemoglobin (g/dL) 0.141
≤ 11 6.6 ± 5.2
> 11 9.5 ± 6.2
PVTT 0.541
Yes 10.2 ± 5.5
No 6.6 ± 4.7
BED (Gy10) 0.836
≤ 65.5 7.2 ± 5.5
> 65.5 15.1 ± 1.6
RT duration (days) 0.443
≤ 37 8.5 ± 5.5
> 37 7.8 ± 2.8
Tumor response <0.001 0.016
Yes 27.8 ± 8.5
No 6.2 ± 2.8
Local control 0.007 0.011
Yes 13.2 ± 4.8
No 7.3 ± 2.6
PVTT portal vein tumor thrombus, HCC hepatocellular carcinoma, ECOG Eastern
Cooperative Oncology Group, BED biologically effective dose, SD standard
deviation, AFP Alpha-fetoprotein
Fig. 1 Overall survival rates according to the response of tumor.
Responders had significantly better survival than non-responders (p< 0.001)
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Patients remained local control after RT had significantly
longer median survival time than patients with progressive
disease (13.2 vs. 7.3 months, p = 0.007; Fig. 2).
Treatment-related toxicity
The toxicities for all patients during RT and 2–3 months
afterward are summarized in Table 5. Most of the acute
gastrointestinal toxicities were self-limited. In terms of
hepatic toxicities, five patients (13.2 %) experienced Com-
mon Terminology Criteria for Adverse Events (CTCAE)
grade 3 or higher transaminase elevation and four of them
simultaneously suffered from grade 3 or higher bilirubin
elevation. One patient experienced RILD according to
prior definition, and transaminase levels of the patient
returned to normal under supportive care at 3 months
after completion of RT. Normal liver volume for this pa-
tient was 423.6 cm3, and lesion size was 9.6 cm in diam-
eter. RT parameters were as follows: prescription dose was
56 Gy in 25 fractions, mean dose to normal liver was 26.8
Gy, and V30 was 26.5 %. For gastrointestinal toxicities,
only one patient experienced a gastric ulcer bleeding at
4 months after RT, but after proton pump inhibitor ther-
apy, he recovered from the ulcer. Four patients had
CTCAE grade 1 or 2 gastroduodenitis or ulcers, and all of
them were transient. There was no treatment-related liver
failure or death in this study.
Discussion
The indication of RT for patients with unresectable HCC
has yet to be defined. HCC is a radiosensitive tumor, but it
is within a considerably radiosensitive organ. In the past,
RT has been considered as palliative and potentially toxic
for HCC patients with underlying cirrhosis. Preservation
of liver function and achievement of tumor control are
equally important for their prognosis [14]. Combining
intensity-modulated and image-guided radiotherapies, HT
Fig. 2 Patients remained local control after radiotherapy had significantly longer median survival time than patients with progressive disease
(13.2 vs. 7.3 months, p = 0.007)
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while sparing most of the normal liver parenchyma to re-
duce hepatic toxicity. In this study, low incidence of severe
liver dysfunction was observed in HCC patients with
underlying cirrhosis receiving HT and objective tumor re-
gression after RT was associated with better prognosis.
For unresectable HCC patients receiving 3D-CRT, some
studies reported tumor response rates ranged from 40 to
72.7 % [15–18]. Kong et al. [15] reported an objective re-
sponse rate of 72.7 % to HT in 22 unresectable HCC pa-
tients. However, only 8 of 20 patients (36.4 %) had PVTT
and may be biased to a high response rate. Kim et al. [16]
reported that an objective response rate for primary liver
tumors after 3D-CRT was 54.3 %, and for PVTT, a re-
sponse rate was 39.0 %. Kang et al. [18] treated 27 HCC
patients with IMRT and reported an objective response
rate of 44.4 %. The study included 18 cases (66.6 %) with
PVTT. Patients with HCC invading portal vein seem to
have lower response rates to RT compared with values
observed in patients with primary HCC. In our study, HTTable 5 Adverse events in the study
No. of patients with CTCAE grade (%)
Adverse event 1 (%) 2 (%) 3 (%) 4 (%)
AST/ALT 21 (55.3) 6 (15.8) 4 (10.5) 1 (2.6)
Alkaline-phosphatase 3 (7.9) – – –
Bilirubin 12 (31.6) 2 (5.3) 3 (7.9) 2 (5.3)
Gastroduodenitis 2 (5.3) 1 (2.6) – –
Gastric ulcer 2 (5.3) – 1 (2.6) –
Duodenal ulcer 1 (2.6) 1 (2.6) – –
CTCAE Common Terminology Criteria for Adverse Events, AST aspartate
aminotransferase, ALT alanine aminotransferasewas delivered to 38 patients with unresectable HCC
and 24 patients (63.2 %) had PVTT. We found a CR
rate of 5.2 % (2/38), a PR rate of 47.4 % (18/38), and an
objective response rate of 52.6 %. With relatively higher
proportion of patients with PVTT, the response rate of
our study is still encouraging.
The survival rate in our study is relatively low com-
pared with values previously reported. Kong et al. [15] re-
ported that 1- and 2-year overall survival rates were 86.4
and 69.1 %, for 22 HCC patients treated with tomother-
apy. McIntosh et al. [19] performed IMRT using HT in 22
HCC patients with or without PVTT. The 1 year overall
survival was 73 % for patients with Child-Pugh class A
disease and 11 % for patients with Child-Pugh class B
disease. Kim et al. [16] treated 70 HCC patients with or
without PVTT by 3D-CRT and reported 1- and 2-year
overall survival rates of 43.1 and 17.6 %, respectively. In
our study, the 1- and 2-year overall survival rates were
56.2 and 31.7 %, respectively. The relatively low survival
rates might be due to inclusion of a larger proportion of
patients with poor prognostic factors such as PVTT,
ECOG scale 2, and Child-Pugh class B disease. It might be
those adverse factors that prompted physicians and pa-
tients to choose HT, aiming to reduce treatment toxicity
with adequate tumor ablation dosage. Although this over-
all survival rate seems relatively low, it is not a low value
when considering that most of the patient population in
our study had advanced HCC and adverse factors.
Several studies have reported that primary tumor re-
sponse was significantly associated with overall survival of
patients with HCC following RT [15, 16, 18]. In our study,
patients achieving objective tumor response (CR + PR)
had a median survival of 27.8 ± 8.5 months, while non-
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1- and 2-year overall survival rate for responders was 68.3
and 57 %, respectively, while non-responders had dismal
overall survival rates. This finding supports that RT can be
one of the treatment options in unresectable HCC pa-
tients who failed to respond to previous treatments. It is
also crucial to identify clinical or molecular parameters
that can predict liver tumor response after RT.
A dose-response relationship in RT for HCC was shown
in some studies. A higher radiation dose was associated
with a higher response rate [20–22] and a higher survival
rate [16, 17]. Some studies failed to show the correlation
between radiation dose and survival [15, 23]. In our stud-
ies, we used BED to analyze the correlation between radi-
ation dose, tumor response, and patient survival because of
a variety of fraction sizes ranging from 1.8 to 2.4 Gy. The
response rates in patients receiving ≤65.5 Gy10 and >65.5
Gy10 were 44.4 and 59.1 %, respectively (p = 0.547). How-
ever, the mean BED of 65.1 ± 18.5 Gy in primary tumor
responders was significantly lower than that of 70.1 ± 16.8
Gy in non-responders (p = 0.045). The mean duration of
RT in tumor responders was shorter than that in non-
responders (36.8 vs. 42.4 days, p = 0.045). As a whole, a
higher BED with a shorter period of RT seemed to result in
higher tumor response rate. Patients receiving >65.5 Gy10
or completing RT ≤37 days had longer median survival
than their respective counterparts. However, it might beTable 6 Comparison of the literatures for helical tomotherapy in pa
Reference No. Fraction
size (Gy)
Total dose (Gy) Target of RT Response (
McIntosh [19] 20 2.5 50 PVTT(+) 40 % PR 6.2
PVTT(−) 60 % SD 87.5
Chi [34] 23 2.5–4.5 52.5 (median) N/A CR 8.6
PR 65.4
Kim [14] 35 4.5–6 50 (range, 45–60) PVTT(+) 100 % CR 14.3
PR 28.6
Kong [15] 20 1.8–4 50–57.5
(range, 30–60)
PVTT(+) 36.4 % CR 18.2
PVTT(−) 63.6 % PR 54.5
Current study 38 1.8–2.4 54 (range, 46–71.8) PVTT(+) 63.2 % CR 5.2
PVTT(−) 36.5 % PR 47.4
RT radiation therapy, PVTT portal vein tumor thrombus, N/A no data, CR complete r
disease, GI gastrointestinal
a1-year overall survival rate (%)due to the small sample size and heterogeneity in stud-
ied cases that these differences were not statistically
significant.
In addition to BED, ECOG score 2, Child-Pugh class
B, hypoalbuminemia, and anemia were factors associated
with poor RT response in our study. Increasing evidence
has shown that the presence of a systemic inflammatory
response correlates with poor prognosis in patients with
advanced cancer [24]. A simple inflammation-based scoring
system, combining C-reactive protein and serum albumin,
is associated with prognosis in patients undergoing cancer
treatments [25, 26]. In our study, hypoalbuminemia was
not only associated with non-response to RT but also with
a low survival rate. Therefore, correction of status of hypo-
albuminemia in HCC patients might be beneficial.
Anemia is common in cancer patients and is considered
to induce tumor hypoxia, which can contribute to radio-
resistance. In addition, numerous studies have shown that
anemia is an independent adverse predictor for overall
survival and local control at various tumor sites [27–29].
We found that patients with hemoglobin >11 g/dL had
better primary tumor response rates following RT
(61.1 vs. 23.1 %, p = 0.035). Median survival rate in pa-
tients with hemoglobin >11 g/dL was 9.5 months, which
was longer than 6.6 months in patients with hemoglobin ≤
11 g/dL. However, the difference failed to show statistical
significance due to small sample size.tients with unresectable hepatocellular carcinoma
%) Median Survival
(months)




9.6 N/A UGI bleeding
1/20
Capecitabine















12.6 1/38 1/38 None
Responder 27.8
Non-responder 6.2
esponse, PR partial response, SD stable disease, RILD radiation-induced liver
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ing RT are gastrointestinal complications such as appetite
loss and gastroduodenal ulcer or bleeding and hepatic
toxicity such as RILD, which was considered the most dis-
mal toxicity due to high fatality. In our study, gastrointes-
tinal toxicities we encountered were manageable. The
incidence of RILD ranged from 0 to 15.4 % [8, 9, 15], and
in our study, RILD was found in one patient (2.6 %),
which was low compared with values previously reported.
Several studies correlated various dose-volumetric param-
eters with the risk of RILD. These included the mean dose
to the normal liver, percentage of the normal liver volume
receiving ≥30 Gy, percentage of the total liver volume re-
ceiving ≥30 Gy, and the normal tissue complication prob-
ability estimates [30–32]. However, the RT technique used
in these studies was mainly 3D-CRT. It might be inappro-
priate to apply these findings to patients receiving IMRT,
which has smaller radiation dose in the liver compared
with 3D-CRT [33]. There is a need of further investiga-
tions about the impact of IMRT on RILD.
3D-CRT and IMRT are able to deliver a conformal ra-
diation dose to cover the target volume while sparing
the critical organs appears attainable [7, 33]. Rotational
IMRT modalities, such as HT, are modern image-guided
intensity-modulated RT techniques. These complex ro-
tational IMRT machines are able to deliver highly con-
formal dose distributions and can spare critical organs
to a greater extent [14, 15, 19]. Several data have shown
that HT has dosimetric advantages over IMRT based on
comparisons in treatment planning. However, there have
been few reports on clinical outcomes for HCC patients
undergoing HT. We present our data and compare it
with other published studies. Table 6 summarizes the
treatment outcomes and toxicity of previously published
studies using HT in the treatment of HCC patients.
Some limitations exist in the current study. First, be-
cause this was a retrospective study, heterogeneity of study
population and dose fractionation schedules were present.
The tumor response to RT might be influenced by frac-
tionated RT dose, but no consensus has been reached on a
standard radiation dose fractionation schedule for patients
with HCC until now. Thus, further research on optimal
fraction size and total dose should be conducted. Second,
the sample size was small and this may minimize the de-
tection of small but clinically important parameters. Third,
the follow-up period was not long. Therefore, long-term
toxicity and quality of life of patients receiving HT for
HCC cannot be evaluated.
Conclusions
Using HT to treat patients with unresectable HCC, we
found that treatment response and overall survival rates
were good with a manageable toxicity even in patients
with poor performance status and PVTT. For responders,the median survival duration was 27.8 months with 1- and
2-year overall survival rates of 68.3 and 57 %, respectively.
The promising results indicate that stricter patient selec-
tion will maximize potential benefits of unresectable HCC
patients receiving RT. Further large-scale, prospective ran-
domized studies are needed to address the efficiency and
optimal dose fraction schedules of RT.
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